Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Naturally Acquired and Conjugate Vaccine-Induced Antibody to <italic>Haemophilus influenzae</italic> Type b (Hib) Polysaccharide in Malian Children: Serological Assessment of the Hib Immunization Program in Mali</title><author><name sortKey="Hutter, Julia" sort="Hutter, Julia" uniqKey="Hutter J" first="Julia" last="Hutter">Julia Hutter</name></author><author><name sortKey="Pasetti, Marcela F" sort="Pasetti, Marcela F" uniqKey="Pasetti M" first="Marcela F." last="Pasetti">Marcela F. Pasetti</name></author><author><name sortKey="Sanogo, Doh" sort="Sanogo, Doh" uniqKey="Sanogo D" first="Doh" last="Sanogo">Doh Sanogo</name></author><author><name sortKey="Tapia, Milagritos D" sort="Tapia, Milagritos D" uniqKey="Tapia M" first="Milagritos D." last="Tapia">Milagritos D. Tapia</name></author><author><name sortKey="Sow, Samba O" sort="Sow, Samba O" uniqKey="Sow S" first="Samba O." last="Sow">Samba O. Sow</name></author><author><name sortKey="Levine, Myron M" sort="Levine, Myron M" uniqKey="Levine M" first="Myron M." last="Levine">Myron M. Levine</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22665612</idno><idno type="pmc">3366516</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366516</idno><idno type="RBID">PMC:3366516</idno><idno type="doi">10.4269/ajtmh.2012.11-0807</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">001605</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001605</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Naturally Acquired and Conjugate Vaccine-Induced Antibody to <italic>Haemophilus influenzae</italic> Type b (Hib) Polysaccharide in Malian Children: Serological Assessment of the Hib Immunization Program in Mali</title><author><name sortKey="Hutter, Julia" sort="Hutter, Julia" uniqKey="Hutter J" first="Julia" last="Hutter">Julia Hutter</name></author><author><name sortKey="Pasetti, Marcela F" sort="Pasetti, Marcela F" uniqKey="Pasetti M" first="Marcela F." last="Pasetti">Marcela F. Pasetti</name></author><author><name sortKey="Sanogo, Doh" sort="Sanogo, Doh" uniqKey="Sanogo D" first="Doh" last="Sanogo">Doh Sanogo</name></author><author><name sortKey="Tapia, Milagritos D" sort="Tapia, Milagritos D" uniqKey="Tapia M" first="Milagritos D." last="Tapia">Milagritos D. Tapia</name></author><author><name sortKey="Sow, Samba O" sort="Sow, Samba O" uniqKey="Sow S" first="Samba O." last="Sow">Samba O. Sow</name></author><author><name sortKey="Levine, Myron M" sort="Levine, Myron M" uniqKey="Levine M" first="Myron M." last="Levine">Myron M. Levine</name></author></analytic><series><title level="j">The American Journal of Tropical Medicine and Hygiene</title><idno type="ISSN">0002-9637</idno><idno type="eISSN">1476-1645</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><italic>Haemophilus influenzae</italic> type b (Hib) conjugate vaccine for infants (6, 10, and 14 weeks of age) was introduced into the Malian Expanded Program on Immunization in July 2005, to diminish invasive Hib disease in young children. Antibodies to Hib capsular polysaccharide (PRP) were measured in infants and toddlers from an area already served by the Hib immunization program (Bamako) and in unimmunized children of the same age in a district (Kangaba) where Hib immunization had not yet begun. Among vaccinated Bamako children 6–23 months of age, 77–93% exhibited PRP titers ≥ 1.0 μg/mL, indicating long-term protection, versus only 10–23% of Kangaba children of that age. High PRP antibody titers in immunized children persisted through 2 years of age. Moreover, ∼50% of Bamako children exhibited anti-PRP titers ≥ 5.0 μg/mL; a level that impedes Hib upper respiratory carriage, and may thereby diminish the Hib transmission to the unimmunized susceptible population (i.e., providing indirect protection).</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Trop Med Hyg</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Trop. Med. Hyg</journal-id><journal-id journal-id-type="publisher-id">tpmd</journal-id><journal-title-group><journal-title>The American Journal of Tropical Medicine and Hygiene</journal-title></journal-title-group><issn pub-type="ppub">0002-9637</issn><issn pub-type="epub">1476-1645</issn><publisher><publisher-name>The American Society of Tropical Medicine and Hygiene</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22665612</article-id><article-id pub-id-type="pmc">3366516</article-id><article-id pub-id-type="doi">10.4269/ajtmh.2012.11-0807</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Naturally Acquired and Conjugate Vaccine-Induced Antibody to <italic>Haemophilus influenzae</italic> Type b (Hib) Polysaccharide in Malian Children: Serological Assessment of the Hib Immunization Program in Mali</article-title><alt-title alt-title-type="left-running-head">HUTTER AND OTHERS</alt-title><alt-title alt-title-type="right-running-head">VACCINE-DERIVED HIB ANTIBODIES IN MALIAN CHILDREN</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hutter</surname><given-names>Julia</given-names></name><xref ref-type="corresp" rid="COR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pasetti</surname><given-names>Marcela F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sanogo</surname><given-names>Doh</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tapia</surname><given-names>Milagritos D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sow</surname><given-names>Samba O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Myron M.</given-names></name></contrib></contrib-group><aff id="AFF1">Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali</aff><author-notes><corresp id="COR1">*Address correspondence to Julia Hutter, University of Maryland School of Medicine, Center for Vaccine Development, 685 W. Baltimore St., Rm. 480, Baltimore, MD 21201. E-mail: <email>jthutter@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>6</month><year>2012</year></pub-date><volume>86</volume><issue>6</issue><fpage>1026</fpage><lpage>1031</lpage><history><date date-type="received"><day>28</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>03</day><month>3</month><year>2012</year></date></history><permissions><copyright-statement>©The American Society of Tropical Medicine and Hygiene</copyright-statement><copyright-year>2012</copyright-year></permissions><abstract><p><italic>Haemophilus influenzae</italic> type b (Hib) conjugate vaccine for infants (6, 10, and 14 weeks of age) was introduced into the Malian Expanded Program on Immunization in July 2005, to diminish invasive Hib disease in young children. Antibodies to Hib capsular polysaccharide (PRP) were measured in infants and toddlers from an area already served by the Hib immunization program (Bamako) and in unimmunized children of the same age in a district (Kangaba) where Hib immunization had not yet begun. Among vaccinated Bamako children 6–23 months of age, 77–93% exhibited PRP titers ≥ 1.0 μg/mL, indicating long-term protection, versus only 10–23% of Kangaba children of that age. High PRP antibody titers in immunized children persisted through 2 years of age. Moreover, ∼50% of Bamako children exhibited anti-PRP titers ≥ 5.0 μg/mL; a level that impedes Hib upper respiratory carriage, and may thereby diminish the Hib transmission to the unimmunized susceptible population (i.e., providing indirect protection).</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0016059 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0016059 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |